Drug Approval | July 26, 2024
Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Alopecia areata usually presents as a few small bald patches in the head
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Subscribe To Our Newsletter & Stay Updated
